U.S. Physical Therapy Lifts Outlook After Record Q2

U.s. Physical Therapy ((USPH)) has held its Q4 earnings call. Read on for the main highlights of the call.

U.S. Physical Therapy’s latest earnings call struck an upbeat tone, underscoring strong operational momentum and disciplined cost control despite persistent reimbursement pressures. Management highlighted record clinic volumes, double‑digit revenue growth in both core physical therapy and injury prevention, expanding margins, and enough confidence to lift full‑year profit guidance even as Medicare cuts and payer changes weigh on earnings.

Record Clinic Volumes Fuel Top-Line Growth

Average visits per clinic per day hit a company record of 32.7 in Q2 2025, up from 30.6 a year earlier, with each month of the quarter sustaining volumes above 32. This higher throughput, totaling more than 1.5 million clinic visits plus nearly 28,500 home‑care visits, provided a key engine for revenue growth and operating leverage across the portfolio.

Physical Therapy Revenue Powered by Metro Deal

Physical therapy revenue climbed to $168.3 million, a 17.3% year‑over‑year increase, with acquisitions doing much of the heavy lifting. The Metro acquisition alone contributed roughly $19.6 million of the growth, illustrating how bolt‑on deals continue to scale the platform and enhance the company’s presence in attractive local markets.

Injury Prevention Segment Delivers Outsized Gains

The injury prevention business posted net revenue growth of 22.6% versus the prior year, with organic revenue up 18.4% and organic gross profit up 21.8%. Segment margin expanded to 22.0% from 21.4%, signaling that this higher‑growth, higher‑margin line is becoming a more meaningful and profitable contributor to consolidated results.

Adjusted EBITDA Rises with Margin Expansion

Adjusted EBITDA reached $26.9 million in Q2, an increase of $4.7 million compared with last year, as margin expanded to 17.5% from 16.4%. The combination of higher volumes, disciplined pricing, and efficient clinic operations is translating into better cash earnings, supporting both reinvestment and shareholder‑friendly capital deployment.

Improved PT Margins and Tight Cost Discipline

Physical therapy gross profit margin improved to 21.1% from 20.1%, reflecting steady cost discipline even in a tight labor market. Salaries and related expenses per visit rose only 0.7% to $60.08, while total operating cost per visit actually declined year over year, underscoring effective management of overhead and clinic‑level efficiency.

Stable Net Rates with Commercial and Workers’ Comp Support

Net rate per visit held essentially flat at $105.33 versus $105.05 a year ago, but underlying dynamics were constructive as commercial rates rose roughly 1.0%–1.5%. Workers’ compensation remained particularly attractive at more than $150 per visit and represented 10.4% of net patient revenue, with visit volumes in that category up 8.4% year over year.

Metro Synergies Lift Pricing and Volumes

Post‑acquisition, Metro’s net rate has steadily improved from about $101 in the initial month to $104.50 in Q1 and $107.50 in Q2, helping overall rate metrics. With Metro clinics averaging about 45 visits per day, the deal is enhancing both pricing and throughput, validating the company’s acquisition playbook and synergy expectations.

Home Care and Cash-Based Services Add New Growth Legs

Management began separately reporting home‑care volumes, disclosing 28,493 visits in the quarter as that channel gains scale and visibility. Meanwhile, newer cash‑based offerings generated roughly $900,000 of incremental revenue in Q2, a modest but growing contribution that diversifies the revenue mix away from traditional insurance reimbursement.

Guidance Raised and Capital Deployment Balanced

Full‑year 2025 adjusted EBITDA guidance was lifted to a range of $93 million to $97 million, with the prior high end now the new low end, reflecting confidence in sustained momentum. Alongside this, the board authorized a share repurchase program of up to $25 million through 2026, even as management reiterated that acquisitions remain the primary use of capital.

Solid Balance Sheet and Interest Rate Visibility

The company ended the quarter with $34.1 million of cash and a $135 million term loan whose interest cost is fixed at 4.7% via swaps through mid‑2027. This rate protection provides earnings visibility despite a higher‑rate environment, while liquidity supports continued deal activity and investment in growth initiatives.

Medicare Cuts Create a Structural Earnings Drag

Management quantified that cumulative Medicare payment reductions have shaved roughly $25 million off profits, with a year‑over‑year hit of $5 million to $6 million amounting to an 8%–8.5% drag on earnings. The company absorbed an additional 2.9% Medicare cut in 2025, underscoring how much recent margin gains reflect internal execution rather than tailwinds from reimbursement.

Michigan Payer Policy Change Dampens Net Rates

A policy shift by the company’s largest payer in Michigan, affecting 56 clinics as of April 1, reduced net rate by about $0.30 per visit. While modest on a per‑visit basis, the breadth of exposure in that state meant the change partially offset otherwise positive pricing trends and highlights the ongoing risk from individual payer decisions.

Same-Store Growth Soft Amid Staffing Constraints

Same‑store growth in mature clinics was just over 1%, below the company’s typical expectations, with several markets still facing staffing tightness. Management suggested that limited clinician availability constrained capacity and likely held back same‑store performance despite robust demand signals in many geographies.

Implementation Costs Weigh but Are Adjusted Out

The company is rolling out enterprise‑wide finance and HR systems through 2026, incurring nonrecurring implementation costs that are added back in adjusted EBITDA. Year‑to‑date selection and related expenses totaled $221,000, and management expects additional costs as the project progresses, representing a near‑term cash and focus drain in exchange for future efficiency.

Seasonality and Working Capital Elevate Variability

June visit volumes dipped to 32.3 per clinic per day, a modest step down consistent with normal summer seasonality that can create quarter‑to‑quarter noise. At the same time, the company’s use of a $175 million revolver, with $245 million drawn as of quarter‑end and cash of $34.1 million, highlighted higher working‑capital needs and leverage tied largely to its acquisition‑led strategy.

Medicare Outlook Offers Limited Near-Term Relief

An early read of the proposed 2026 fee schedule points to only a modest Medicare uplift of roughly 1.0%–1.75%, which could add about $2 million to $3 million of revenue and $1.5 million to $2.5 million of EBITDA. That improvement, while welcome, would not come close to reversing the roughly $25 million cumulative hit from prior cuts, leaving reimbursement risk an enduring overhang.

Guidance and Outlook Emphasize Confidence Amid Headwinds

In raising full‑year adjusted EBITDA guidance to $93 million–$97 million, management credited record visit levels, improving PT margins, strong injury prevention growth, and tight cost control. They also pointed to stable net rates, higher workers’ comp volumes, and emerging contributions from home care and cash‑pay services as reasons to expect continued earnings growth despite reimbursement and staffing challenges.

U.S. Physical Therapy’s call painted a picture of a company offsetting structural reimbursement headwinds with volume growth, acquisitions, and operating discipline. While Medicare cuts, payer changes, and staffing remain key risks, rising margins, expanded guidance, and new revenue channels suggest the business is finding multiple levers to protect profitability, making the stock a name to watch for investors seeking healthcare services exposure.